L3VLUP
ProSign in

ENOV · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ENOVLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ENOV
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterENOVLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 2021none listed holders, n.a.31 holders, $29.9bn
Q4 2021none listed holders, n.a.31 holders, $34.7bn
Q1 20221 holders, $163m24 holders, $35.3bn
Q2 20224 holders, $572m33 holders, $42.7bn
Q3 20227 holders, $193m31 holders, $43.4bn
Q4 20227 holders, $225m31 holders, $46.6bn
Q1 20237 holders, $214m33 holders, $44.3bn
Q2 20238 holders, $187m37 holders, $59.6bn
Q3 20235 holders, $135m44 holders, $67.6bn
Q4 20236 holders, $112m45 holders, $73.6bn
Q1 20245 holders, $158m41 holders, $95.3bn
Q2 20246 holders, $106m43 holders, $110bn
Q3 20245 holders, $23m45 holders, $107bn
Q4 20244 holders, $40m46 holders, $93.9bn
Q1 20256 holders, $66m42 holders, $98.4bn
Q2 20254 holders, $33m43 holders, $93.2bn
Q3 20253 holders, $19m39 holders, $86.7bn
Q4 20254 holders, $52m41 holders, $123bn
Q1 20261 holders, $1.0m39 holders, $106bn
Q2 20261 holders, $916k44 holders, $132bn
ENOV

Enovis Corporation

Holders
5
Reported value
$23m
Buyers
2
Sellers
2

Breadth 0 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
45
Reported value
$107bn
Buyers
24
Sellers
22

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ENOV (3)

First Eagle Investment Management LLC, PDT Partners LLC, Southeastern Asset Management Inc

Only LLY (43)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, and 18 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →